J7530: Mycophenolate mofetil (myhibbin), oral suspension, 5 mg
J7530 is a HCPCS Level II code for mycophenolate mofetil (myhibbin), oral suspension, 5 mg. It belongs to the Drugs Administered Other Than Oral Method section. Whether Medicare pays it depends on the coverage rule below.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q4-Oct. This states Medicare’s position on the code, not on your particular claim.
The CMS record for J7530
- Long descriptor
- Mycophenolate mofetil (myhibbin), oral suspension, 5 mg
- Short descriptor
- Mycophenolat (myhibbin) 5 mg
- Added
- October 1, 2026
- BETOS
- O1E
- Pricing indicator
- 51: Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
Berenson-Eggers Type of Service: CMS's own analytic grouping.
Drugs.
Codes adjacent to J7530
HCPCS has no hierarchy: related items simply sit next to each other in the numbering. If J7530 is not quite right, the correct code is very often within a few positions of it.
- J7520Sirolimus, oral, 1 mg
- J7521Tacrolimus, granules, oral suspension, 0.1 mg
- J7524Mycophenolate mofetil, oral, 5 mg
- J7525Tacrolimus, parenteral, 5 mg
- J7526Injection, mycophenolate mofetil, 5 mg
- J7527Everolimus, oral, 0.25 mg
- J7528Mycophenolate mofetil, for suspension, oral, 100 mgterminated
- J7529Mycophenolate mofetil, for suspension, oral, 5 mg
- J7531Prednisolone sodium phosphate, orally disintegrating tablet, 1 mg
- J7599Immunosuppressive drug, not otherwise classified
- J7601Ensifentrine, inhalation suspension, fda approved final product, non-compounded, administered through dme, unit dose form, 3 mg
- J7604Acetylcysteine, inhalation solution, compounded product, administered through dme, unit dose form, per gram
- J7605Arformoterol, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 15 micrograms
- J7606Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms
- J7607Levalbuterol, inhalation solution, compounded product, administered through dme, concentrated form, 0.5 mg
- J7608Acetylcysteine, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per gram